Skip to main content

Disclaimer

In the Downloads section, the ‘Prior Submission’ file reflects the most recent measure submission to the former CBE. This file is provided for transparency. For any questions or clarification, please contact the designated measure steward.

History of Prostate Cancer - Cancer Surveillance

CBE ID
0625
Endorsement Status
1.0 New or Maintenance
1.1 Measure Structure
Previous Endorsement Cycle
Is Under Review
No
1.6 Measure Description

The percentage of men with definitively treated localized prostate cancer who had at least one PSA level in the past 12 months.

    Measure Specs
      General Information
      1.14 Numerator

      Men who had at least one PSA level in the past 12 months.

      1.15 Denominator

      Men with localized prostate cancer who were treated with curative intent.

      Exclusions

      1. Surgical treatment for prostate cancer in the past year
      2. Drug treatment for prostate cancer in the past year
      3. Radiation therapy for prostate cancer in the past year
      4. Prostate MRI in past year
      5. Prostate biopsy in the past year
      6. Metastatic prostate cancer
      7. Provider or patient feedback stating patient does not have a diagnosis of prostate cancer.
      8. General exclusions
      a. Terminal Illness
      b. Active treatment of malignancy (chemotherapy or radiation therapy) in the past 6 months.
      c. Patients who were admitted to a skilled nursing facility in the past 3 months.

      Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Cancer Endorsement Maintenance Project
      Initial Endorsement
      Last Updated
      Removal Date
      Steward Organization
      ActiveHealth Management
      Steward POC email
      Steward Organization Copyright

      This information, including any attachments hereto, is the sole, exclusive, proprietary and confidential property of ActiveHealth Management, Inc., and is for the exclusive use of The National Quality Forum. Any use, copying, disclosure, dissemination or distribution by anyone other than the National Quality Forum is strictly prohibited.

                Public Comments